

## 393 **Online Methods**

394

### 395 **Bacterial strains, plasmids and growth conditions**

396 All bacteriological culture media were obtained from Oxoid or Difco. For mating procedures  
397 and extraction of plasmid and genomic DNA, *C. difficile* strains were cultured in BHIS  
398 broth<sup>29</sup>, supplemented with 0.1% L-cysteine HCl and 0.375% glucose, or BHIS agar  
399 supplemented with 0.09% FeSO<sub>4</sub>. Cefoxitin and thiamphenicol (Sigma) were used at 25 µg  
400 ml<sup>-1</sup> and 10 µg ml<sup>-1</sup>, respectively. *C. difficile* cultures were grown in an atmosphere of 10%  
401 H<sub>2</sub>, 10% CO<sub>2</sub> and 80% N<sub>2</sub> at 37°C in a Coy anaerobic chamber. *E. coli* strains were  
402 derivatives of either DH5α (Life Technologies) or S17-1<sup>30</sup>. *E. coli* strains were cultured  
403 aerobically at 37°C in 2xYT agar or broth<sup>31</sup>. Where appropriate, *E. coli* cultures were  
404 supplemented with chloramphenicol, erythromycin or ampicillin, at 30 µg ml<sup>-1</sup>, 150 µg ml<sup>-1</sup>,  
405 100 µg ml<sup>-1</sup>, respectively.

406

### 407 **Isolation and manipulation of nucleic acids**

408 Plasmid DNA was isolated from *E. coli* strains grown overnight in 5 ml of broth, with  
409 appropriate antibiotic selection, using Qiaprep spin miniprep columns (Qiagen), following  
410 the manufacturer's instructions. *E. coli* transformations were performed using the Pipes  
411 method<sup>32</sup>. *C. difficile* genomic DNA was prepared as previously described<sup>13</sup>. Standard  
412 methods were used for the digestion, modification, ligation, and analysis of plasmid and  
413 genomic DNA and PCR products<sup>33</sup>. Oligonucleotide primers used in this study are listed in  
414 Supplementary Information. Nucleotide sequencing reactions were carried out using a  
415 PRISM™ Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Applied  
416 Biosystems), according to the manufacturer's instructions. Sequence detection was carried  
417 out on an Applied Biosystems 3730S Genetic Analyser by Micromon at Monash University  
418 and sequences were analyzed using Sequencher™ 3.1 software (Gene Codes  
419 Corporation).

420

### 421 **QRT-PCR analysis of PaLoc gene expression**

422 The procedure was carried out essentially as before<sup>34</sup>. In brief, RNA was extracted from 40  
423 ml of *C. difficile* cultures grown to an OD<sub>600</sub> of approximately 0.3 for *tcdC* gene expression  
424 analysis, and from 10 ml of *C. difficile* cultures grown to an OD<sub>600</sub> of approximately 1.8 for  
425 all other PaLoc gene expression analysis, using the Ribopure Bacteria kit (Ambion Inc.),  
426 according to the manufacturer's instructions. To remove contaminating genomic DNA, the  
427 purified RNA was treated with the DNA-free kit (Ambion Inc.), according to the

428 manufacturer's instructions. Reverse transcription reactions were then performed using 2  
429 µg of purified RNA, 0.5 µM primer, and the Omniscript Reverse Transcription Kit (Qiagen)  
430 according to the manufacturer's instructions. Prior to real-time PCR analysis all RT  
431 reactions were diluted 2-fold and 5-fold. Reactions were then performed in a final volume  
432 of 25 µl with SYBR Green PCR master mix (Applied Biosystems), 2 µl of diluted RT  
433 reactions and 120 nM primers using an Eppendorf Realplex<sup>4</sup> Mastercycler. Triplicate  
434 reactions were performed in multiple experiments using RNA from three biological  
435 replicates. The data were normalised to *C. difficile* *rpoA* RNA levels. Primers used for  
436 QRT-PCR are listed in Supplementary Information.

437

#### 438 **Construction of toxin A- and toxin B-specific recombination vectors**

439 Oligonucleotide primers JRP2342 and JRP2343 were used to amplify the 566 bp region  
440 corresponding to nt 1071-1637 of *tcdA* (Accession number M30307). The corresponding  
441 region of *tcdB* (Accession number X53138) was amplified using JRP2344 and JRP2345.  
442 Since *EcoRI* restriction sites had been incorporated into the primers, this enzyme was  
443 used to clone the products into the corresponding site of the shuttle vector pJIR1456<sup>35</sup>  
444 (Accession number U90554) to construct the *tcdA*- and *tcdB*-targeted recombination  
445 vectors pJIR3051 and pJIR3050, respectively.

446

#### 447 **Isolation of chromosomal *C. difficile* mutants**

448 To construct *C. difficile* strains with mutations resulting from insertion of the recombination  
449 vectors in the *tcdA* or *tcdB* genes, the vectors pJIR3051 and pJIR3050 were introduced  
450 into *E. coli* strain S17-1, respectively. Strain S17-1 carries a chromosomal copy of the  
451 broad host-range plasmid RP4 and although it is not able to self-transfer it provides all the  
452 functions required to mobilize co-resident IncP *oriT* plasmids. The *oriT*-containing plasmids  
453 pJIR3051 and pJIR3050 were therefore transferred by conjugation to *C. difficile* strain  
454 JIR8094, as previously described<sup>13</sup>. In the final step, the growth from each non-selective  
455 plate was resuspended in 1 ml of BHI diluent (0.37% BHI, 0.01% sodium thioglycollate)  
456 and 100 µl spread onto BHIS agar supplemented with thiamphenicol and cefoxitin, the  
457 latter antibiotic being used as a counter selection against *E. coli*. The plates were  
458 incubated anaerobically at 37°C for at least 72 h, until colonies were observed. The  
459 colonies then were subcultured onto the same medium and incubated for a further two to  
460 three days. Subcultures that showed bacterial growth were subcultured twice more, then  
461 analyzed by PCR, Southern blotting and plasmid rescue experiments.

462

### 463 **Southern hybridization analysis of *C. difficile* strains**

464 Genomic *C. difficile* DNA was digested with *Xba*I, subjected to agarose gel electrophoresis  
465 and then transferred to a Nylon H+ Hybond membrane (Amersham)<sup>33</sup>. Southern  
466 hybridization analysis was then carried out on the resultant membrane using standard  
467 methods<sup>36</sup>. DNA probes were digoxigenin (DIG)-labeled by random PCR labeling,  
468 following the manufacturer's instructions (Roche). The blots were hybridized with probes  
469 specific for *tcdA* (the 566 bp PCR product of primers JRP2342/JRP2343), *tcdB* (the 566 bp  
470 JRP2344/JRP2345 PCR product), and *catP* (0.73 kb product amplified from pJIR1456  
471 using primers JRP2142/JRP2143<sup>13</sup>).

472

### 473 **Partial purification of toxins from culture supernatants**

474 The toxins were partially purified by ammonium sulphate precipitation from culture  
475 supernatants. Briefly, *C. difficile* was grown overnight in 20 ml of 2TY broth (3.0% tryptone,  
476 2.0% yeast extract and 0.1% sodium thioglycollate) and approximately 3 ml transferred to  
477 90 ml of the same medium. The cultures were then grown for 3 days, after which time the  
478 cells were pelleted by centrifugation (10,000 x g, 15 min, room temperature). The  
479 supernatants were then filter sterilized (0.45 µm filters) and solid ammonium sulphate was  
480 added with stirring at room temperature, to reach 70% saturation, followed by incubation  
481 for 20 min at 4°C. The precipitated protein was collected and dissolved in 2 ml of water  
482 and dialyzed overnight at 4°C in PBS, with four changes of buffer.

483

### 484 **Toxin A-specific Western Blots**

485 Partially purified toxin proteins were subjected to SDS-PAGE and transferred by  
486 electrophoresis to nitrocellulose membranes (Whatman), as previously described<sup>34</sup>. The  
487 membranes were incubated for 1 h in PBS containing 5% dry milk powder and then  
488 incubated overnight with affinity purified polyclonal goat antibodies specific for *C. difficile*  
489 toxin A (Techlab). Toxin A-bound antibodies were then detected with peroxidase-  
490 conjugated anti-goat antibodies (Chemicon) and the Western lightning chemiluminescence  
491 reagent kit (Perkin-Elmer), according to the manufacturer's instructions.

492

### 493 **Vero and HT-29 cell cytotoxicity assays**

494 To prepare the supernatants used in the toxin assays, *C. difficile* was grown as before in  
495 90 ml of TY broth for 3 days, and the cells pelleted by centrifugation as before. The  
496 supernatants were filter sterilized and stored on ice prior to use. Vero and HT-29 cells  
497 were cultured in minimum essential medium (MEM alpha medium: GIBCO™, Invitrogen) or

498 McCoy's medium (5A medium modified: GIBCO™, Invitrogen), respectively, containing  
499 10% heat inactivated fetal calf serum (HI FCS), 100 units/ml penicillin and 100 µg/ml  
500 streptomycin in culture flasks at 37°C in 5% CO<sub>2</sub>. The cells were grown to a confluent  
501 (Vero) or semi-confluent (HT-29) monolayer and subcultured by incubation in 1 to 2 ml of  
502 0.1% trypsin in 1 mM EDTA. The cells were counted and resuspended in fresh medium at  
503 a concentration of  $0.25 \times 10^5$  (Vero) or  $5.0 \times 10^5$  (HT-29) cells/ml. One ml of the cell  
504 suspension was seeded into each well of 24-well plates. The plates were incubated for 20  
505 to 24 h and the culture medium removed, after which cells were washed with PBS. Serial  
506 two-fold dilutions of the *C. difficile* culture supernatants were made in PBS and 100 µl  
507 added to each well, followed by 400 µl of MEM or McCoy's medium containing 1% HI  
508 FCS. Negative controls were treated with 500 µl of fresh medium. The plates were  
509 incubated at 37°C in 5% CO<sub>2</sub>. The morphological changes were observed by microscopy  
510 after 24 h. The cytopathic effect (CPE) was determined on a scale from 0 to +4 in  
511 comparison to the negative control wells. The end-point was scored as the last dilution at  
512 which 100% or 4+ CPE was observed. The assays were performed in triplicate on  
513 independent culture supernatants. An Olympus 1X71 inverted microscope was used to  
514 visualise the cells at 10X and 20X magnifications.

515

#### 516 **Toxin neutralization assays**

517 For neutralization of toxin activity, affinity purified polyclonal antibodies specific to toxin A  
518 (goat anti-TcdA, Techlab) and toxin B (rabbit anti-TcdB, tgcBIOMICS) were used.  
519 Neutralization assays were performed by incubating filtered supernatants with  
520 appropriately diluted antibodies for 90 min at room temperature before the addition of the  
521 treated supernatant to Vero or HT-29 cell monolayers, together with growth medium  
522 supplemented with 1% HI FCS. As a negative control, culture supernatants were treated  
523 with a polyclonal antibody reactive against the ErmB RNA methylase.

524

#### 525 **Anaerobic *C. difficile* adherence assays**

526 Quantification of *C. difficile* adhesion to host cells was achieved by an anaerobic bacterial  
527 adherence assay that used a derivative of the Caco-2 human intestinal epithelial cell-line,  
528 Caco-2BBE (C2BBE). C2BBE host cells express the human sodium-glucose transporter  
529 SGLT1 and elaborate a brush-border when cultured in monolayers. C2BBE cells were  
530 cultured in high-glucose (25 mM) Dulbecco's Minimal Eagle Medium (DMEM), 10% fetal  
531 bovine serum, 20 mM HEPES, 100 units ml<sup>-1</sup> penicillin, and 100 mg/ml streptomycin at  
532 37°C in the presence of 5% CO<sub>2</sub>. Cells between passages 25 and 45 were grown as

533 confluent monolayers ( $1.2 \times 10^6$  cells) in 6-well plates, and transferred to antibiotic and  
534 serum-free DMEM 24 hours prior to adherence assays. For the assays, C2BBE plates  
535 were introduced into the anaerobic chamber just before use, serum-free medium was  
536 removed and exponentially-growing *C. difficile* strains applied at a multiplicity of infection  
537 of 20 in a volume of 2 ml. All bacterial strains used were washed and resuspended in  
538 completely anaerobic DMEM with 25 mM  $\text{CaCl}_2$  prior to incubation with host cells.  
539 Adherence was allowed to proceed under anaerobic conditions for 40 min. Host cells and  
540 adherent bacteria were then washed twice with 1 ml of completely anaerobic phosphate-  
541 buffered saline (PBS), scraped, serially diluted and plated to enumerate adherent *C.*  
542 *difficile*. Each experiment was performed in quadruplicate, and repeated at least three  
543 times in its entirety. The percent adherence was calculated as the ratio of recovered *C.*  
544 *difficile* to input *C. difficile* multiplied by 100. The SPSS software package was used for  
545 statistical analyses. Significance ( $P < 0.01$ ) was determined using ANOVA to enable  
546 comparison between multiple groups of continuous numerical data. The Least Significant  
547 Difference test was used for post hoc analyses.

548

#### 549 **Hamster experiments**

550 *C. difficile* strains were tested in groups of 10 specific pathogen-free, 90-100 g Syrian  
551 hamsters. To minimize contamination, hamsters were housed in individual isolator cages  
552 fitted with air filters on their lids. Cages, food, water bottles, water, and bedding were  
553 autoclaved, and personnel handling the animals wore disposable gowns, masks, hats,  
554 shoe covers, and gloves. Each experimental group was housed in a separate room to  
555 prevent cross-contamination with different strains of *C. difficile*<sup>23,37</sup>.

556

557 To prepare spores, *C. difficile* strains were streaked heavily and grown anaerobically at  
558 37°C on anaerobic blood agar plates (BBL anaerobic blood agar plates, Columbia base,  
559 Fisher L21928) to confluency, with an incubation time of 5 to 6 days to induce sporulation.  
560 The organisms were then harvested with disposable loops, placed into 10 ml of PBS,  
561 washed in PBS, and heat-shocked at 56°C for 10 min to kill surviving vegetative cells. The  
562 spores were centrifuged and resuspended in Dulbecco's modified Eagle medium (DMEM),  
563 aliquoted, and frozen at -80°C. The frozen spores were then quantified before use by  
564 plating 10-fold serial dilutions of the spores onto taurocholate-fructose-agar plates. The  
565 agar base was taurocholate-cefoxitin-cycloserine-fructose-agar (TCCFA), but without  
566 cycloserine and cefoxitin<sup>23</sup>. Spores were diluted in DMEM prior to inoculation.

567

568 For each test strain, hamsters were given clindamycin orogastrically (30 mg/kg), to render  
569 them susceptible to *C. difficile* infection (day zero). On study day five hamsters received  
570 1000 cfu of *C. difficile* spores by gastric inoculation. Hamsters were then monitored twice  
571 daily for 5 days and daily thereafter. Animal bedding was changed and fecal pellets were  
572 collected daily. Specimens were inoculated onto selective TCCFA plates and incubated  
573 anaerobically at 37°C to determine if they were colonized with *C. difficile*. Fecal pellets  
574 were collected daily for 12 days, then weekly until termination of the study (up to 30 days).  
575 *C. difficile* isolates from at least three colonized hamsters per group were typed by  
576 restriction endonuclease analysis (REA) to confirm the identity of the infecting *C. difficile*  
577 isolate<sup>38</sup>. Hamsters groups were assessed for colonization, time interval between  
578 challenge with *C. difficile* and colonization and time interval between colonization and  
579 death. Note that this study was approved by the Institutional Animal Care and Use  
580 Committee (IACUC) at the Hines VA Hospital.

581

582 The wild type parent strain JIR8094 and two independently derived toxin A (*tcdA*Ω1 and  
583 *tcdA*Ω2, JIR8253 and JIR8263, respectively) and toxin B mutants (*tcdB*Ω1 and *tcdB*Ω2,  
584 JIR8253 and JIR8263, respectively) were each analyzed in groups of 10 hamsters. During  
585 the hamster experiments with the second group of independent mutants, fecal pellets from  
586 all of the *C. difficile*-colonized hamsters were analyzed for stability of the toxin A or toxin B  
587 mutation. Fecal samples taken after colonization were homogenized in 3.75 ml of PBS  
588 and serially diluted and subcultured onto TCCFA. For each hamster, 100 *C. difficile*  
589 colonies were then individually patched onto BHIS agar containing cefoxitin and  
590 thiamphenicol, to confirm that the *catP* antibiotic resistance marker from the recombination  
591 plasmid was still present and onto BHIS agar containing cefoxitin as a positive control for  
592 growth. Hamster fecal pellets, homogenized in 0.75 ml PBS were also analyzed for the  
593 presence of toxin A, using a toxin A-specific ELISA (TechLab) and for the presence of  
594 toxin B using a human foreskin fibroblast cytotoxicity assay (human foreskin fibroblast cell  
595 monolayers, Diagnostic Hybrids; anti-*C. difficile* toxin, Trinity Biotech).

596

597 For the toxin A ELISA, 0.2 g of homogenized fecal pellet sample was added to 0.2 ml of  
598 diluent and mixed. The samples were clarified by centrifugation and the assay performed  
599 according to the manufacturer's instructions. The OD<sub>450nm</sub> was determined using a  
600 microtiter plate reader (Bio-Rad). Samples were considered positive if their OD<sub>450nm</sub> was at  
601 least 0.19, and negative if their OD<sub>450nm</sub> was less than 0.05; there were no intermediate  
602 results. For the toxin B cytotoxicity assay, 0.1 g of homogenized fecal sample was mixed

603 with 0.5 ml of diluent and mixed. The samples were clarified by centrifugation, filtered  
604 through 0.45 µm pore filters (Millipore), and the assay performed according to the  
605 manufacturer's directions. The cytotoxic effect was recorded at 24 h and all positive results  
606 were confirmed by neutralization with antitoxin. Results were recorded as negative (-),  
607 weak cytotoxicity (+; less than 10% cell rounding), or high cytotoxicity (+++; greater than  
608 80% cell rounding), there were no intermediate results. REA typing was performed and  
609 analyzed as previously described<sup>37</sup>.

610

## 611 **Additional References**

612

613 <sup>31</sup> Miller, J. H., *Experiments in molecular genetics*. (Cold Spring Harbor Laboratory,  
614 Cold Spring Harbor, NY, 1972).

615 <sup>32</sup> Inoue, H., Nojima, H., and Okayama, H. High efficiency transformation of  
616 *Escherichia coli* with plasmids. *Gene* **96**, 23-28 (1990).

617 <sup>33</sup> Sambrook, J. and Russell, D. W., *Molecular cloning: a laboratory manual*. (Cold  
618 Spring Harbor Laboratory Press., Cold Spring Harbor, NY., 2001).

619 <sup>34</sup> Carter, G. P. *et al.* Binary toxin production in *Clostridium difficile* is regulated by  
620 CdtR, a LytTR family response regulator. *J. Bacteriol.* **189**, 7290-7301 (2007).

621 <sup>35</sup> Lyras, D. and Rood, J. I. Conjugative transfer of RP4-*oriT* shuttle vectors from  
622 *Escherichia coli* to *Clostridium perfringens*. *Plasmid* **39**, 160-164 (1998).

623 <sup>36</sup> Lyras, D. and Rood, J. Transposition of Tn4451 and Tn4453 involves a circular  
624 intermediate that forms a promoter for the large resolvase, TnpX. *Mol. Microbiol.* **38**,  
625 588-601 (2000).

626 <sup>37</sup> Razaq, N. *et al.* Infection of hamsters with historical and epidemic BI types of  
627 *Clostridium difficile*. *J Infect.Dis.s* **196**, 1813-1819 (2007).

628 <sup>38</sup> Clabots, C. R. *et al.* Development of a rapid and efficient restriction endonuclease  
629 analysis typing system for *Clostridium difficile* and correlation with other typing  
630 systems. *J. Clin. Microbiol.* **31**, 1870-1875 (1993).

631

632